GeneTAG Technology

GeneTAG TechnologyGeneTAG TechnologyGeneTAG Technology
Home
Products
About Us
Contact us

GeneTAG Technology

GeneTAG TechnologyGeneTAG TechnologyGeneTAG Technology
Home
Products
About Us
Contact us
More
  • Home
  • Products
  • About Us
  • Contact us

  • Home
  • Products
  • About Us
  • Contact us

Drug-resistance mutations in EGFR

Non-small cell lung cancer (NSCLC) drug-resistance qPCR probe panel

NSCLC accounts for 85–90% of all lung cancers and is driven by alterations in oncogenes, such as EGFR. Variable exon 19 deletions in codons 746–753 and the L858R point mutation account for ~90% of all activating EGFR mutations in NSCLC and respond well to the first-generation tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. GeneTAG has developed a nearly comprehensive set of iDDS probe assays for EGFR mutations that confer resistance or show susceptibility to first-, second-, or third-generation TKIs used in NSCLC. The performance of each probe is shown below. Feel free to let us know if you would like more info regarding drug-resistance and drug-susceptibility profiles.

Advantages of iDDS probes

Our iDDS probe assays have competitive antiprobes, which block false-positives. This strategy enables unparalleled accuracy. For example, several probes in our NSCLC drug-resistance panel accurately detected the target template, but not 6 closely related targets.

Get quote

GeneTAG Technology, Inc.

Copyright © 2023 GeneTAG Technology - All Rights Reserved.

Powered by GoDaddy